Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionRegions Financial Corp
Latest Disclosed Ownership1,300 shares
Latest Disclosed Value $ 580,502
Regions Financial Corp reports 17.22% increase in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 5, 2026 - Regions Financial Corp filed a 13F-HR form disclosing ownership of 1,300 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $580,502 USD as of March 31, 2026. The entity filed a previous 13F-HR on January 27, 2026 disclosing 1,109 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of 17.22% during the quarter. The current value of the position is $556,842 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-05 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,300 191 17.22 581 15.54 0.0038
2026-01-27 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 1,109 462 71.41 503 98.42 0.0032
2025-11-19 2025-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 647 -90 -12.21 253 -22.87 0.0017
2025-11-19 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 647 -90 253 0.0016
2025-07-29 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 737 30 4.24 328 -4.09 0.0023
2025-05-08 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 707 51 7.77 343 29.55 0.0026
2025-02-14 2024-12-31 13F Vertex Pharmaceuticals COM 92532F100 656 -352 -34.92 264 -43.59 0.0019
2024-11-14 2024-09-30 13F Vertex Pharmaceuticals COM 92532F100 1,008 -16 -1.56 469 -2.30 0.0034
2024-07-31 2024-06-30 13F Vertex Pharmaceuticals COM 92532F100 1,024 270 35.81 480 52.06 0.0036
2024-04-23 2024-03-31 13F Vertex Pharmaceuticals COM 92532F100 754 54 7.71 315 10.92 0.0024
2024-02-06 2023-12-31 13F Vertex Pharmaceuticals COM 92532F100 700 -565 -44.66 285 -35.31 0.0023
2023-11-01 2023-09-30 13F Vertex Pharmaceuticals COM 92532F100 1,265 -10 -0.78 440 -2.01 0.0040
2023-08-09 2023-06-30 13F Vertex Pharmaceuticals COM 92532F100 1,275 -28 -2.15 449 0.0039
2023-05-12 2023-03-31 13F Vertex Pharmaceuticals COM 92532F100 1,303 -62 -4.54 0 0.0037
2023-02-06 2022-12-31 13F Vertex Pharmaceuticals COM 92532F100 1,365 -2 -0.15 0 -100.00 0.0036
2022-11-03 2022-09-30 13F Vertex Pharmaceuticals COM 92532F100 1,367 -392 -22.29 396 -20.00 0.0040
2022-07-25 2022-06-30 13F Vertex Pharmaceuticals COM 92532F100 1,759 -307 -14.86 495 -8.16 0.0047
2022-04-25 2022-03-31 13F Vertex Pharmaceuticals COM 92532F100 2,066 -952 -31.54 539 -18.70 0.0044
2022-01-31 2021-12-31 13F Vertex Pharmaceuticals COM 92532F100 3,018 -1,346 -30.84 663 -16.18 0.0052
2021-11-04 2021-09-30 13F Vertex Pharmaceuticals COM 92532F100 4,364 -7,668 -63.73 791 -67.39 0.0068
2021-07-27 2021-06-30 13F Vertex Pharmaceuticals COM 92532F100 12,032 -53,803 -81.72 2,426 -82.85 0.0210
2021-06-02 2021-03-31 13F Vertex Pharmaceuticals COM 92532F100 65,835 -7,951 -10.78 14,148 -18.87 0.1282
2021-02-05 2020-12-31 13F Vertex Pharmaceuticals COM 92532F100 73,786 -270 -0.36 17,439 -13.46 0.1681
2020-10-15 2020-09-30 13F Vertex Pharmaceuticals COM 92532F100 74,056 5,750 8.42 20,152 1.62 0.2198
2020-07-27 2020-06-30 13F Vertex Pharmaceuticals COM 92532F100 68,306 6,911 11.26 19,830 35.74 0.2308
2020-04-29 2020-03-31 13F Vertex Pharmaceuticals COM 92532F100 61,395 -1,469 -2.34 14,609 6.14 0.1944
2020-02-03 2019-12-31 13F Vertex Pharmaceuticals COM 92532F100 62,864 -182 -0.29 13,764 28.86 0.1444
2019-10-24 2019-09-30 13F Vertex Pharmaceuticals COM 92532F100 63,046 4,401 7.50 10,681 -0.69 0.1186
2019-07-19 2019-06-30 13F Vertex Pharmaceuticals COM 92532F100 58,645 12,672 27.56 10,755 27.17 0.1213
2019-04-19 2019-03-31 13F Vertex Pharmaceuticals COM 92532F100 45,973 44,231 2,539.09 8,457 2,836.46 0.0974
2019-01-28 2018-12-31 13F Vertex Pharmaceuticals COM 92532F100 1,742 -2,107 -54.74 288 -61.19 0.0036
2018-10-22 2018-09-30 13F Vertex Pharmaceuticals COM 92532F100 3,849 -1,036 -21.21 742 -10.71 0.0080
2018-07-26 2018-06-30 13F Vertex Pharmaceuticals COM 92532F100 4,885 -2,158 -30.64 831 -27.61 0.0094
2018-04-18 2018-03-31 13F Vertex Pharmaceuticals COM 92532F100 7,043 -2,526 -26.40 1,148 -19.94 0.0129
2018-01-18 2017-12-31 13F Vertex Pharmaceuticals COM 92532F100 9,569 -1,778 -15.67 1,434 -16.87 0.0155
2017-10-23 2017-09-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 11,347 -4,135 -26.71 1,725 -13.53 0.0196
2017-07-31 2017-06-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 15,482 -76,766 -83.22 1,995 -80.22 0.0234
2017-05-02 2017-03-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 92,248 -18,664 -16.83 10,087 23.45 0.1194
2017-02-03 2016-12-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 110,912 -5,921 -5.07 8,171 -19.80 0.1000
2016-10-28 2016-09-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 116,833 -5,351 -4.38 10,188 -3.06 0.1313
2016-07-26 2016-06-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 122,184 5,942 5.11 10,510 13.74 0.1363
2016-05-02 2016-03-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 116,242 10,478 9.91 9,240 -30.57 0.1225
2016-01-29 2015-12-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 105,764 7,030 7.12 13,308 29.43 0.1785
2015-10-20 2015-09-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 98,734 10,659 12.10 10,282 -5.46 0.1465
2015-07-14 2015-06-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 88,075 72,950 482.31 10,876 509.64 0.1444
2015-04-23 2015-03-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 15,125 3,035 25.10 1,784 24.23 0.0229
2015-01-21 2014-12-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 12,090 -278 -2.25 1,436 3.31 0.0186
2014-10-27 2014-09-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 12,368 -1,002 -7.49 1,390 9.79 0.0173
2014-07-23 2014-06-30 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 13,370 2,986 28.76 1,266 72.48 0.0155
2014-04-17 2014-03-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 10,384 1,111 11.98 734 6.53 0.0093
2014-01-27 2013-12-31 13F VERTEX PHARMACEUTICALS COMMON STOCK 92532F100 9,273 9,273 689 0.0085
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.